Market state
The UK and Ireland life sciences sector is entering 2026 with a renewed sense of momentum. After a difficult 2025, in which vacancies fell 6.8% in the UK and a sharper 27.6% in Ireland, both markets are now showing clear signs of recovery. Across the region, hiring is forecast to grow by 13.3% in the UK and 7.7% in Ireland this year and having spent the past twelve months speaking with clients navigating that downturn, it's genuinely encouraging to see confidence returning.
This shift isn't happening by accident. Government backing through the UK's Life Sciences Sector Plan, faster clinical trial approvals, and more than £3 billion in public and private investment are giving organisations the confidence to move research programmes from planning into delivery. In Ireland, targeted investment in quality control, validation engineering and clinical operations is underpinning a similar, if more measured, resurgence, supported by initiatives such as the EU Biotech Act and Research Ireland's €460 million funding commitment.
What stands out most to me is how the nature of hiring itself is changing. Employers are no longer chasing volume; they're being deliberate, prioritising specialist scientific, regulatory and clinical talent capable of supporting increasingly complex, high-value programmes. That's a meaningful shift for recruitment partners and candidates alike, and it's reshaping where the real competition for talent is happening, from R&D and biotechnology through to medical affairs and quality assurance.
